# US 2015/0104491 A1 · Sustained-release reservoir implants for intracameral drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104491 A1
- Document ID: US20150104491A1
- Status: Published application
- Kind: A1
- Application number: 14/482,039
- Filed: 2014-09-10
- Published: 2015-04-16
- Earliest claimed: 2010-04-06
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Ruiwen Shi; Patrick M. Hughes; James A. Burke; Michael R. Robinson; Hui Liu
- Web page: https://patentgrep.com/patent/US20150104491A1

## CPC

- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 31/382: having six-membered rings, e.g. thioxanthenes (thiothixene A61K31/496)
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/5578: having a pentalene ring system, e.g. carbacyclin, iloprost
- A61P 9/12: Antihypertensives
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.

## Claims

### Claim 1

A sustained release implant for intraocular use to treat elevated intraocular pressure, configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient, wherein said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive into said eye for a period of time of between 12 days and 365 days.

### Claim 2 (depends on 1)

The implant of claim 1, wherein said polymer is a nonbiodegradable polymer.

### Claim 3 (depends on 2)

The implant of claim 2, wherein said polymer is selected from the group consisting of silicone elastomers, poly(ethylene-co-vinylacetate) and polyurethane.

### Claim 4 (depends on 1)

The implant of claim 1, wherein said polymer is a biodegradable polymer.

### Claim 5 (depends on 4)

The implant of claim 4, wherein said polymer is an aliphatic polyester.

### Claim 6 (depends on 1)

The implant of claim 1, wherein antihypertensive agent is selected from the group consisting of hypotensive lipids, beta-adrenergic receptor antagonists, alpha-adrenergic agonists, sympathomimetics, miotic agents, carbonic anhydrase inhibitors, Rho-kinase inhibitors, calcium channel blockers, vaptans (vasopressin-receptor antagonists,) and cannabinoids.

### Claim 7 (depends on 6)

The implant of claim 6, wherein antihypertensive agent is selected from the group consisting of bimatoprost, latanoprost, travoprost, unoprostone, EP2/EP4 receptor agonists, timolol, betaxolol, levobetaxolol, carteolol, levobunolol, propranolol, brimonidine, apraclonidine, epinephrine, dipivefrin, pilocarpine, dorzolamide, brinzolamide, acetazolamide, Rho-kinase inhibitors, Latrunculin B compound, PF-04217329, PF-03187207, AR-102, AL-6221, AL-3789, calcium channel blockers, vaptans, anecortave acetate and analogues, ethacrynic acid and cannabinoids.

### Claim 8 (depends on 6)

The implant of claim 6, wherein antihypertensive agent is a combination of ocular anti-hypertensives.

### Claim 9 (depends on 8)

The implant of claim 8, wherein said combination is selected from the group consisting of bimatoprost/timolol, travoprost/timolol, latanoprost/timolol, brimonidine/timolol, and dorzolamide/timolol.

### Claim 10 (depends on 1)

The implant of claim 1, wherein said antihypertensive agent is an EP2 agonist.
